Adobe’s CTO has sailed into the sunset to “pursue other opportunities.” Now, the web is buzzing about what those new opportunities might be.
Herrod will lead the firm’s investment focus in “next generation infrastructure technologies.”
Nile Therapeutics, a Berkeley, Calif., biotech hired Peter Strumph, formerly chief of operations for struggling heart-drug maker CV Therapeutics, as CEO. Nile is currently developing a second-generation natriuretic peptide, CD-NP, for the treatment of heart failure. Here’s hoping it fares better than the first-generation version of this drug, J&J’s Natrecor. The company’s release is here.